P. Wilson

发表

Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage

H. Lenz, P. Wilson, W. Fazzone, 2008, Nucleic acids research.

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)

W. Zhang, G. Folprecht, K. Danenberg, 2012, The Pharmacogenomics Journal.

Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.

C. Caldas, P. Johnston, D. Longley, 2006, Cancer research.

Integrating biomarkers into clinical decision making for colorectal cancer.

H. Lenz, P. Wilson, Heinz-Josef Lenz, 2010, Clinical colorectal cancer.

Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan

P. Johnston, D. Longley, P. Wilson, 2004, Clinical Cancer Research.

mline Polymorphisms in Genes Involved in the IGF 1 hway Predict Efficacy of Cetuximab in Wild-type R S mCRC Patients

H. Lenz, A. Gerger, P. Wilson, 2010 .

Calbindin 2 (CALB2) Regulates 5-Fluorouracil Sensitivity in Colorectal Cancer by Modulating the Intrinsic Apoptotic Pathway

P. Johnston, D. Longley, P. Wilson, 2011, PloS one.

The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells

P. Johnston, D. Longley, P. Wilson, 2007, Molecular Cancer Therapeutics.

The dual EGFR/HER‐2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN‐38

H. Lenz, P. Wilson, W. Fazzone, 2009, International journal of cancer.

Predictive and prognostic markers in colorectal cancer.

H. Lenz, P. Wilson, R. Ladner, 2007, Gastrointestinal cancer research : GCR.

Novel opportunities for thymidylate metabolism as a therapeutic target

N. Neamati, J. Deng, P. Wilson, 2008, Molecular Cancer Therapeutics.

GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients.

M. Shah, H. Lenz, W. Zhang, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2

J. Barrett, G. Folprecht, P. Wilson, 2008 .

Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

P. Johnston, H. Lenz, P. Wilson, 2014, Nature Reviews Clinical Oncology.

Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer

H. Lenz, A. El-Khoueiry, A. Gerger, 2011, Clinical Cancer Research.

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

H. Lenz, H. Chang, A. El-Khoueiry, 2008, Clinical Cancer Research.

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

H. Lenz, A. El-Khoueiry, P. Wilson, 2011, Cancer research.

A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates

P. Wilson, M. LaBonte, R. Ladner, 2011, Nucleic acids research.

Common Cancer Stem Cell Gene Variants Predict Colon Cancer Recurrence

M. Kahn, H. Lenz, A. El-Khoueiry, 2011, Clinical Cancer Research.

Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models

H. Lenz, P. Wilson, M. LaBonte, 2011, International journal of cancer.

An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence

M. Shah, H. Lenz, W. Zhang, 2012, The Pharmacogenomics Journal.

Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma

Laura H. Tang, M. Shah, H. Lenz, 2011, International journal of cancer.

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

H. Lenz, A. Gerger, P. Wilson, 2010, Clinical Cancer Research.

Molecular Markers in the Treatment of Metastatic Colorectal Cancer

H. Lenz, P. Wilson, M. LaBonte, 2010, Cancer journal.

Assessing the in vivo efficacy of biologic antiangiogenic therapies

H. Lenz, P. Wilson, M. LaBonte, 2012, Cancer Chemotherapy and Pharmacology.

Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer

H. Lenz, P. Wilson, M. LaBonte, 2011, Molecular Cancer Therapeutics.

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

S. Groshen, H. Lenz, A. El-Khoueiry, 2010, Cancer Chemotherapy and Pharmacology.

Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen

H. Lenz, W. Zhang, A. Gerger, 2013, The Pharmacogenomics Journal.

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

M. Kahn, H. Lenz, W. Zhang, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular markers in radically resected colorectal cancer: from prognosis to prediction

H. Lenz, P. Wilson, Wu Zhang, 2013 .

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

H. Lenz, A. El-Khoueiry, W. Zhang, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer

H. Lenz, A. El-Khoueiry, P. Wilson, 2013, Investigational New Drugs.

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

Susan Groshen, S. Groshen, H. Lenz, 2009, BMC Medical Genomics.

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells

H. Lenz, P. Wilson, W. Fazzone, 2009, International journal of cancer.

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer

P. Wilson, M. LaBonte, R. Ladner, 2021, npj Breast Cancer.

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer

P. Wilson, M. LaBonte, R. Ladner, 2021, NPJ breast cancer.

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer

H. Lenz, W. Zhang, A. Gerger, 2014, The Pharmacogenomics Journal.

Using The Colon Cancer Multigene Recurrence Score to Determine Risk: Prognostic Milestone or a Step in the Right Direction?

H. Lenz, P. Wilson, P. Bohanes, 2010 .

Therapeutic Discovery Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase – Targeted Therapies in Non – Small Cell Lung Cancer

H. Lenz, P. Wilson, M. LaBonte, 2012 .

Exploring alternative individualized treatment strategies in colorectal cancer.

H. Lenz, P. Wilson, R. Ladner, 2007, Clinical colorectal cancer.

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

H. Lenz, P. Wilson, M. LaBonte, 2011, Pharmacogenomics.

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer

H. Lenz, M. Pishvaian, P. Wilson, 2016, Molecular Cancer Therapeutics.

Genes involved in EGFR-degradation to predict for efficacy in metastatic colorectal cancer patients treated with cetuximab.

H. Lenz, P. Wilson, M. LaBonte, 2013 .

Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.

D. Kerr, D. Bissett, P. Wilson, 1993, Cancer research.

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

H. Lenz, A. El-Khoueiry, P. Wilson, 2011, Cancer research.

Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).

D. Bissett, P. Wilson, P. Vasey, 1995, Cancer research.

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines

P. Wilson, W. Fazzone, M. LaBonte, 2009, BMC Medical Genomics.